Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 28

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 28
---
 even where the acquisition could be beneficial to you.

We may be required to repurchase certain of our warrants.

Certain of our outstanding warrants sold privately that have registration rights, in the event of a “Fundamental Transaction” (as defined in the applicable warrants) that is not within the Company’s control, including not approved by the Company’s Board of Directors, the holder of such warrant shall only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of such warrant, that is being offered and paid to the holders of the Company’s common stock in connection with the Fundamental Transaction, which may materially adversely affect our financial condition and/or results of operations and may prevent or deter a third party from acquiring us.

<div align='center'>13</div>

The Series Warrants may not have any value.

Each Series A Warrant offered hereby will become exercisable immediately at an exercise price of $ per share of Series B Preferred Stock and will expire five years from the date of the Initial Conversion Date. Each Series B Warrant offered hereby will become exercisable immediately at an exercise price of $ per share of Series B Preferred Stock and will expire on the one (1) year anniversary of the Initial Conversion Date. If we do not obtain the Stockholder Approval to increase the number of our authorized shares of common stock in an amount sufficient to issue shares issuable upon conversion of Series B Preferred Stock issued upon exercise of the Series Warrants included in this offering, the Series Warrants included in this offering may not have any value and you could lose part or all of your investment.

We do not currently have a sufficient number of authorized shares of common stock to cover the shares issuable upon conversion of the Series B Preferred Stock being offered by this prospectus. As a result, before the Series B Preferred Stock can become convertible, we need to receive stockholder approval of the Charter Amendment (which is an amendment to our Charter to sufficiently increase our authorized shares of common stock to cover the conversion of all outstanding shares of Series B Preferred Stock into common stock). We have agreed in the securities purchase agreement in connection with this offering to use our reasonable best efforts to obtain such approval within 60 days from the closing of this offering, and the Company agreed to cause an additional stockholder meeting to be held every ninety days thereafter until (i) such Stockholder Approval is obtained, or (ii) December 31, 2025, whichever is